BMR Related Analyst Ratings
-
Stifel Nicolaus Upgrades BioMed Realty (BMR) to Buy
-
KeyBanc Upgrades BioMed Realty (BMR) to Buy
-
KeyBanc Upgrades BioMed Realty (BMR) to Hold, Overhang Could Be Lifted
-
Jefferies Maintains a 'Hold' on BioMed Realty (BMR); Q2 Review: Signs of Life
-
Cantor Fitzgerald Upgrades BioMed Realty (BMR) to Buy; Growing Demand...For Labs
-
Stifel Nicolaus Downgrades BioMed Realty (BMR) to Hold
-
Stifel Nicolaus Upgrades BioMed Realty (BMR) to Buy
-
Cantor Fitzgerald Starts BioMed Realty (BMR) at Hold; Leasing Up Well But Risk Remains
-
JPMorgan and KeyBanc Hit 'Refresh Button' on REIT Stocks
-
KeyBanc Overweight on Specialty Office/Industrial Outlook: Favors COR & DFT
-
KeyBanc Downgrades BioMed Realty (BMR) to Underweight; Valuation Appears Rich
-
Raymond James Downgraded Several REIT Stocks; Raises Rating on NNN & DEI
-
Raymond James Downgrades BioMed Realty (BMR) to Outperform
-
Morgan Stanley Downgrades BioMed Realty (BMR) to Equalweight
-
BMO Capital Downgrades BioMed Realty (BMR) to Market Perform, Cuts Price Target to $19
-
Jefferies Upgrades BioMed Realty (BMR) to Buy
-
Wells Fargo Downgrades BioMed Realty (BMR) to Market Perform; Shares Now Fall Within Valuation Range
-
FBR Capital Reiterates an 'Outperform' on BioMed Realty (BMR); Leasing Momentum Should Continue
-
KeyBanc on REITs: Updating FFO Estimates for Several Companies Ahead of Q1
-
FBR Capital Riterates an 'Outperform' on BioMed Realty (BMR); Unsecured Offering Dilutes, but Leasing News Is Encouraging
-
FBR Capital: Ratcheting REIT Returns--Raising RMZ Target to 840
-
FBR Capital Upgrades BioMed Realty (BMR) to Outperform; Move-out Risk Priced In
-
Jefferies Lowers Estimates & Price Target on BioMed Realty (BMR), Maintains Hold Rating
-
Correction - Stifel Nicolaus Downgrades BioMed Realty (BMR) to Hold
-
FBR Capital Reiterates a 'Market Perform' on BioMed Realty (BMR); Acquisitions Continue to Support FFO Growth
-
FBR Capital Upgrades BioMed Realty (BMR) to Market Perform; Sleight of Acquisition
-
Cowen & Co Initiates Coverage on Several REITs
-
FBR Capital Maintains 'Underperform' on BioMed Realty Trust (BMR); Updating Assumptions Related to South San Francisco Acquisition
-
FBR Capital Maintains an 'Underperform' on BioMed Realty Trust (BMR), However, Acquisitions Reduce Core Operating Risk
-
Jefferies Starts BioMed Realty Trust (BMR) at Hold
-
Jefferies & Co Initiates Coverage on Several REIT Stocks
-
FBR Capital Downgraded BioMed Realty Trust (BMR) to Underperform
-
FBR Capital on Office REITs--Increasing Price Targets on Lower IRRs/Cap Rates
-
FBR Capital 2Q10 Office REIT Earnings Recap--Don't Read the Guidance by the Cover
-
Macquarie Initiates Coverage on BioMed Realty Trust (BMR) with an Outperform
-
FBR Capital Initiates Coverage on Nine Office/Specialty REITs
-
Wells Fargo Upgrades BioMed Realty Trust (BMR) to Outperform; Upside Potential, Downside Limited
-
UBS Downgrades Numerous Real Estate Stocks: PSA, EDR, DFT to Neutral, HCP, ESS, O to Sell
-
Stifel Nicolaus Upgrades BioMed Realty Trust (BMR) to Buy
-
Raymond James Upgrades BioMed Realty Trust (BMR) to Strong Buy
-
BMO Capital Initiates Coverage on BioMed Realty Trust (BMR) with an Outperform
-
FBR Upgrades BXP, BMR to Outperform, Downgrades AVB, EQR to Market Perform
-
RBC Capital Upgrades BioMed Realty Trust (BMR) to Sector Perform
-
FBR Capital Upgrades AVB, EQR, HME, UDR, WRE, DEI, DRE; Downgrades BMR, BXP, KRX, AMB, PLD
-
Baird Upgrades BioMed Realty Trust (BMR) to Outperform
-
Oppenheimer Downgrades Several REITs
-
UBS Downgrades BioMed Realty Trust (BMR) to Neutral
-
Oppenheimer Upgrades BioMed Realty Trust (BMR) to Outperform
-
Merrill Lynch Upgrades BioMed Realty (BMR) to Neutral
-
Oppenheimer Initiates Coverage on BioMed Realty Trust (BMR)
Back to BMR Stock Lookup
